Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

Cross-off #6

The Agreement is an LOI to in-license Ph. II drug candidate L-Dopa-Induced Dyskinesia PD from an undisclosed 3rd party - one of several suggested Pharma's:

1.) Endo Pharmaceuticals (Amantadine)
2.) Adamas Pharmaceuticals (Nurlin)
3.) Novartis Pharmaceuticals (Mavoglurant)
4.) Addex Therapeutics (Dipraglurant)
5.) Psychogenics Pharmaceuticals (Eltoprazine)
6.) Avanir Pharmaceuticals (Nuedexta)
7.) Neurim Pharmaceuticals (Neu-120)